Transcode Therapeutics (RNAZ) Profit After Tax (2020 - 2026)

Transcode Therapeutics (RNAZ) has 7 years of Profit After Tax data on file, last reported at -$19.5 million in Q1 2026.

• Quarterly Profit After Tax fell 61.44% year-over-year to -$19.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$43.7 million (down 71.06% YoY) and the FY2025 annual result came in at -$36.3 million, down 116.09% from the prior year.
• Profit After Tax retreated to -$19.5 million in Q1 2026, from -$15.1 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of -$2.3 million in Q3 2024 to a low of -$19.5 million in Q1 2026.
• A 5-year average of -$6.4 million and a median of -$4.8 million in 2023 frame the typical range for Profit After Tax.
• Annual changes were most pronounced in 2022 — Profit After Tax plunged 268.58% — and 2024, when it surged 56.2%.
• Tracing RNAZ's Profit After Tax over 5 years: stood at -$5.1 million in 2022, then grew by 20.38% to -$4.1 million in 2023, then tumbled by 45.48% to -$5.9 million in 2024, then sank by 153.14% to -$15.1 million in 2025, then slipped by 29.61% to -$19.5 million in 2026.
• The last three Profit After Tax figures came in at -$19.5 million (Q1 2026), -$15.1 million (Q4 2025), and -$4.9 million (Q3 2025), per Business Quant data.